NTLA-2001

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

CardiomyopathyHereditary Transthyretin Amyloidosis

91 competitors in Cardiomyopathy

#DrugCompanyPhaseTrials

1

Dobutrex

Eli Lilly

Phase 3

12

Plaquenil

Alnylam Pharmaceuticals

Phase 3

13

Vyndaqel

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 3

34

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

15

Wainua (autoinjector)

AstraZeneca

Phase 3

26

Immunoglobulins

CSL Behring

Phase 3

17

Cialis

Eli Lilly

Phase 2

38

Aldactone

Pfizer

Phase 2

29

Betaseron

Bayer

Phase 2

110

Cellcept

Roche

Phase 2

1Show 29 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hereditary Transthyretin Amyloidosis1 trial

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

Completed·Intellia Therapeutics·Phase 1·NCT04601051·72 enrolled

Cardiomyopathy1 trial

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Active, not recruiting·Intellia Therapeutics·Phase 3·NCT06128629·1,200 enrolled

Details

Drug Info

Related News